Israel: Last News

Do reinfections increase long Covid risks?

Vaccination and long COVID There could be other reasons for the positive trend that we’ve witnessed, but the timing suggests that vaccination is the most likely explanation. The decrease in referrals begins in August 2021, around five months after the British population started receiving second doses of COVID-19 vaccines.

There is some evidence already to suggest that immunity gained from vaccination protects against long COVID, though the size of the effect differs between studies. For example, one study from the US showed a 15% reduction in long COVID symptoms after vaccination, a study from the UK saw a 50% reduction, while one study from Israel found vaccination was associated with no long COVID symptoms at all.

The reason for these differences will have a lot to do with testing methods. For instance, how long after COVID-19 did the researchers survey symptoms? What symptoms constitute long COVID, and how severe do these symptoms need to be to qualify? While it’s difficult to pin down the degree to which vaccination reduces long COVID symptoms, we believe it has played a key role in the reduction in new referrals we’ve seen in our clinic.

The fact that other groups, using different measuring techniques, have also observed this association is very reassuring. Reinfections We’re now in a phase of the pandemic where reinfections are increasingly common and will probably soon constitute most infections.

This leads us to an important question: does reinfection carry the same risk (or even an increased risk) of long COVID, compared with previous infections? If it does, we would be in big trouble as each reinfection will lead to more and more people with long COVID, eventually overwhelming health services. But this assumes

. vaccine symptoms infection

Related News

ATAGI recommendations on first booster dose in adolescents aged 12-15 years - - Usa - Israel - Australia - Denmark
ATAGI recommendations on first booster dose in adolescents aged 12-15 years
1-3 There is currently insufficient evidence that a first booster dose provides additional protection against severe disease for most children and adolescents in this age group.Adolescents aged 12-15 years who are at an increased risk of severe disease may receive a first booster dose From first principles, ATAGI have identified three groups of adolescents aged 12-15 years who may be at greater risk of severe disease from COVID-19 compared to their peers:A first booster dose of COVID-19 vaccine may offer additional protection against severe disease, noting the overall risk of admission to an intensive care unit and death in this age group remains very low.1-3 There have been no confirmed deaths from COVID-19 in Australian adolescents aged 12-15 years during the period of Omicron predominance.1,2 Most European and North American countries have also recorded no deaths except for England (1), Denmark (5), and the United States (17).3 These data reflect deaths in adolescents aged 12-15 years with concurrent SARS-CoV-2 since February 1, 2022, and do not necessarily attribute cause of death to COVID-19.Myocarditis following vaccination remains rare. Data from the United States and Israel suggest the risk of myocarditis following a third dose of the Pfizer COVID-19 vaccine in male adolescents aged 12-15 years ranges from 1 in 11 000-58 000 doses.